Literature DB >> 2459641

A clinical comparison of central and peripheral argon laser panretinal photocoagulation for proliferative diabetic retinopathy.

G W Blankenship1.   

Abstract

Fifty eyes with three or four diabetic retinopathy risk factors received argon laser panretinal photocoagulation (PRP) with treatment randomly assigned to either central or peripheral distribution. Six months after treatment, two or more acuity lines had been lost by 24% of the central PRP, and by only 8% of the peripheral PRP eyes. Mean visual field constriction with the I-4e isopter was 39% for the central and 29% for the peripheral PRP eyes; for the IV-4e isopter, it was 12 and 7%. Pretreatment macular thickening increased in 19% of the central PRP eyes, but decreased in 19% of the peripheral PRP eyes (P less than 0.05). There was complete disc neovascular regression in 38% of the central and 47% of the peripheral PRP eyes. Partial regression was obtained in 31% centrally and 33% peripherally treated eyes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459641     DOI: 10.1016/s0161-6420(88)33212-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  14 in total

Review 1.  Anti-vascular endothelial growth factor for neovascular glaucoma.

Authors:  Arathi Simha; Andrew Braganza; Lekha Abraham; Prasanna Samuel; Kristina Lindsley
Journal:  Cochrane Database Syst Rev       Date:  2013-10-02

2.  The effect of short versus long exposure times of argon laser panretinal photocoagulation on proliferative diabetic retinopathy.

Authors:  E C Wade; G W Blankenship
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

Review 3.  Laser photocoagulation for proliferative diabetic retinopathy.

Authors:  Jennifer R Evans; Manuele Michelessi; Gianni Virgili
Journal:  Cochrane Database Syst Rev       Date:  2014-11-24

4.  Extended targeted retinal photocoagulation versus conventional pan-retinal photocoagulation for proliferative diabetic retinopathy in a randomized clinical trial.

Authors:  Homayoun Nikkhah; Hossein Ghazi; Mohammad Reza Razzaghi; Saeed Karimi; Alireza Ramezani; Masoud Soheilian
Journal:  Int Ophthalmol       Date:  2017-02-06       Impact factor: 2.031

5.  Observations on the lobular organization of the human choriocapillaris.

Authors:  A W Fryczkowski; M D Sherman; J Walker
Journal:  Int Ophthalmol       Date:  1991-03       Impact factor: 2.031

6.  Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings.

Authors:  Alexander J Brucker; Haijing Qin; Andrew N Antoszyk; Roy W Beck; Neil M Bressler; David J Browning; Michael J Elman; Adam R Glassman; Jeffrey G Gross; Craig Kollman; John A Wells
Journal:  Arch Ophthalmol       Date:  2009-02

7.  Reduction of severe macular edema in eyes with poor vision after panretinal photocoagulation for proliferative diabetic retinopathy.

Authors:  T W Gardner; A W Eller; T R Friberg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

8.  Visual field loss with capillary non-perfusion in preproliferative and early proliferative diabetic retinopathy.

Authors:  C K Chee; D W Flanagan
Journal:  Br J Ophthalmol       Date:  1993-11       Impact factor: 4.638

Review 9.  A chronic grey matter penumbra, lateral microvascular intussusception and venous peduncular avulsion underlie diabetic vitreous haemorrhage.

Authors:  David McLeod
Journal:  Br J Ophthalmol       Date:  2007-05       Impact factor: 4.638

10.  Diabetic choroidal and iris vasculature scanning electron microscopy findings.

Authors:  A W Fryczkowski; B L Hodes; J Walker
Journal:  Int Ophthalmol       Date:  1989-07       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.